ArchiveInhalation therapy is the superior choice for treating respiratory diseases. Unlike traditional methods of drug administration, inhalation therapy requires the use of inhalation devices to deliver the drugs to targeted areas. Innovations in inhalation devices aim to improve the delivery efficiency, reduce the impact of respiratory flow rate on drug delivery and improve patient compliance. This paper reviews the development trends of oral inhalation devices and their progress in intelligentization. The soft mist inhaler based on innovative microfluidic nebulization technology and its nebulization mechanism and delivery characteristics are analyzed and discussed. Moreover, this paper further elaborates on the different stages of the development of intelligent inhalation devices. The impact of intelligent inhalation devices on patient compliance is also discussed, providing a reference for further research on intelligent inhalation devices.
In recent years, pulmonary infectious diseases have posed a serious threat to human health. Compared with the traditional oral and injection administration routes, inhalation administration is increasingly used to treat pulmonary infectious diseases. This route can achieve targeted delivery of drugs to the infected sites, and has the advantages of improving the pulmonary bioavailability, reducing systemic adverse reactions and drug resistance, and therefore has gained widely concern. This paper summarizes the research progress of inhalation preparations for treatment of pulmonary infectious diseases, with a view to providing references for the research and development of anti-infective drugs for pulmonary inhalation.
Unlike traditional dry powder inhalers that provide directly inhalable drug-containing powders, the electrical heating vaporization inhalation device vaporizes the drug through rapid heating, then makes the drug cool in the inspiratory airflow to form aerosol to be inhaled. Therefore, it is critical to control the degree of drug degradation in the process of vaporization and ensure that the formed aerosol has good delivery efficiency. This study was conducted by the self-made rapid heating and adjustable electrical heating vaporization device with edaravone(with low melting point and boiling point) and risperidone(with high melting point and boiling point) as the model drugs. The stainless steel sheet material, drug-coating layer thickness and heating vaporization temperature were optimized to control thermal degradation and improve delivery efficiency. The results showed that the purity of risperidone aerosol could be significantly increased from 39.31% to 95.77% after the stainless steel sheet was treated at 500 ℃ for 30 min. Edaravone with drug loading of 1.9 mg had high emitted doses and aerosol purity(above 99.8%) at the vaporization temperatures of 311 and 357 ℃. At the vaporization temperature of 357 ℃, risperidone with a drug loading of 0.5 mg also showed high emitted doses and aerosol purity. And the fine particle fraction(FPF) of both model drugs through electrical heating vaporization inhalation were over 95%, indicating good lung delivery characteristics.
As a new biological material, exosomes have the characteristics of specificity, presentation, tumor-promoting, immune escape and induction, which are being widely used in clinical medicine. However, the specific molecular mechanism has not yet been clarified. Due to the unclear side effects of exosomes in functional applications, balancing the interests of exosomes is the key to use exosomes for treatment and diagnosis effectively. At the same time, it is necessary to simplify and improve the separation and extraction technologies of exosomes, increase production and reduce costs in order to realize the industrial production and application. It is a core to find a way to obtain high purity specific exosomes and ensure production supply. In this manuscript, the basic information, the biological function characteristics of exosomes, and the preparation process of engineering exosomes are summarized. In addition, the technologies and products from relevant commercial companies in this filed are sorted out, which provides insights to further explore the application of exosomes.
Exosomes are nanovesicles secreted by cells. As a natural drug carrier, exosomes have attracted extensive attention from researchers. Exosomes show good biocompatibility, low immunogenicity, targeting, and long-circulating, but low drug-loading capacity. Hybridizing exosomes with synthetic nanocarriers to construct hybrid exosome vesicles can not only retain the original advantages of exosomes but also improve the drug-loading capacity and obtain new biological functions. This review comprehensively summarizes the different types of exosomes and nanocarriers used in the construction of hybrid exosome vesicles, concludes the related preparation methods, and discusses the advantages of the hybrid exosome vesicles as nanoscale drug delivery systems and their critical common problems that need to be solved.
Intravesical instillation is of great significance to prevent tumor recurrence after bladder cancer surgery. Therefore, developing sustained-release preparations for perfusion delivery and highly effective drug combinations plays an important role in improving the efficacy, shortening the administration period and enhancing the patient compliance. In this review, drugs(traditional antineoplastics, monoclonal antibodies, nucleic acid drugs, etc.) for bladder perfusion and novel drug delivery systems(liposomes, micelles, nanoparticles, hydrogels, etc.) for perfusion delivery used in the treatment of bladder cancer in recent years are summarized in order to provide new approaches for intravesical drug delivery.
Drug-device combination products have become a hot spot of innovation with the rapid development of modern science and technology. Drug-device combined products integrate the functions of medicines and medical devices, so they generally have the characteristics of high risk and complex technical performance. The development of drug-device combination products in China is still in its infancy and the regulatory system needs to be gradually improved. The guidances issued by U.S. FDA describe the key role of human factors engineering in the development of drug-device combination products, as well as the importance of human factors engineering to product safety and effectiveness. The relatively mature review thinkings of U.S. FDA might have a positive role in promoting the understanding of human factors engineering and evaluation of some related indicators for drug-device combination products of regulatory authorities in China.
Owing to simple preparation process, high drug loading capacity and strong adhesion, nanocrystals can effectively solve the problems of short-term retention time, slow release rate and low bioavailability of poorly water-soluble drugs. Therefore, it has become a hot research topic in pharmaceutics in recent years. In this paper, the preparation technologies of nanocrystals and their research progress of applications in mucosal drug delivery systems such as nasal, ocular, oral, skin and pulmonary delivery systems are reviewed, hoping to provide a reference basis for the development of nanocrystal-based dosage forms of poorly soluble drugs.
Baicalein, a flavone derived from Scutellaria baicalensis, exhibits antitumor effect by suppressing tumor cell proliferation, inducing tumor cell apoptosis, inhibiting tumor angiogenesis, and regulating the tumor microenvironment. However, its poor solubility has attenuated the bioavailability and thus restricting the efficacy. Many studies utilize nano-drug delivery systems to improve bioavailability and antitumor efficacy of baicalein. This review summarizes the recent studies concerning the antitumor mechanisms of baicalein and its nano delivery systems to provide approaches for its further basic research and clinical application.
Continuous flow process for the synthesis of losartan(1) was realized by microchannel reactor technology based on the synthetic routes reported in the literature. Compound 1 was obtained with an overall yield of 70.3%[based on 2-cyano-4'-methylbiphenyl(2)] via bromination, N-alkylation and tetrazolium cycloaddition reaction using 2 and 2-butyl-4-chloro-1H-imidazole-5-carboxaldehyde(3) as the starting materials. The optimized process bearing mild reaction conditions, simple operation and higher security is suitable for industrial production.
An improved synthetic process of roxadustat(1) was reported. Methyl 4-hydroxy-7-phenoxyisoquinoline-3-carboxylate(2) was chlorinated by 1,3-dichloro-5,5-dimethylhydantoin to obtain methyl 1-chloro-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate(3), 3 was transformed into 1-methyl-4-hydroxy-7-phenoxyisoquinoline-3-carboxylic acid(4) through coupling reaction with methylboronic acid and hydrolysis. Then 4 was amidated with glycine methyl ester hydrochloride to generate methyl (1-methyl-4-hydroxy-7-phenoxyisoquinoline-3-carbonyl)-glycinate(5). Finally, the target compound 1 was obtained from 5 by hydrolysis reaction with a purity of 99.9% and an overall yield of 60.8%(based on 2). The optimized process was easy to operate and had been verified by pilot test, which was suitable for industrial production.
In order to control the quality of varenicline tartrate, four related substances, namely 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine-1-oxide(related substance A), 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine-1,4-dioxide(related substance B), 1,5,6,7,8,9-hexahydro-5,9-methanoimidazo[4,5-h][3]benzazepine(related substance C) and 7,8,9,10-tetrahydro-8-nitroso-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine(related substance D), were synthesized based on the synthetic process of varenicline tartrate. The structures of these related substances were confirmed by HRMS, 1H NMR and 13C NMR.
Using adipic acid dihydrazide(ADH) as a linkage, the polymer hyaluronic acid(HA)-ADH-artesunate(1) was synthesized. Then, the polymeric micelles of HA-ADH-1 were prepared by ultrasonic dispersion. Their characteristics in vitro and anti-inflammatory effects in vitro and in vivo were investigated. The observation of transmission electron microscopy revealed that the HA-ADH-1 micelles was spherical, and the results of dynamic light scattering showed that the average particle size of HA-ADH-1 micelles was 170.90 nm. The cumulative release at 48 h of 1 from HA-ADH-1 micelles in the physiological environment(pH 7.4) was less than 50%, which was much lower than that of free 1, indicating that HA-ADH-1 micelles had sustained-release property and stable structure. The cytotoxicity and uptake assay results showed that HA-ADH-1 micelles could bind to CD44 receptors highly expressed on the macrophage surface, showing specific targeting to inflammatory macrophages induced by lipopolysaccharide, then enhanced the intracellular accumulation of 1. Therefore, the micelles demonstrated a better killing effect on inflammatory macrophages.
Ciclopirox olamine(1) microsponges were prepared by quasi emulsion solvent diffusion method. The effects of mass ratio of polymer(ethyl cellulose) to 1, polyvinyl alcohol concentration and stirring speed on the encapsulation rate and yield of 1 microsponges were investigated with single factor test and Box-Behnken design combined with response surface methodology. The optimal formulation and process parameters were as follows: the mass ratio of ethyl cellulose to 1 was 2.40∶1, the concentration of polyvinyl alcohol was 2.68%, and the stirring speed was 350 r/min. The optimized microsponges had a porous spherical structure with uniform particle size distribution, the volume mean diameter and surface mean diameter were (67.60±0.47) and (57.03±0.80)μm, respectively. In saline containing 30% polyethylene glycol 400, the cumulative release rate at 8 h of the bulk drug reached (74.85±0.60)%, while the cumulative release rate at 48 h of 1 microsponges was (72.81±1.08)%, indicating that the microsponges had a certain sustained-release effect.
The formulation parameters for dry granulation of Chaiyin granules were determined by taking the primary forming rate, hygroscopicity and solubility as the evaluation indicators, and the physical characteristics of the granules obtained by wet granulation process as reference. Single factor method and Box Behnken design-response surface methodology were used to optimize dry granulation process parameters. The quality of the granules prepared by dry granulation and wet granulation was compared. The results showed that the Chaiyin granules prepared by the optimized dry granulation process had high primary forming rate, low friability and good fluidity, which could meet the needs of industrial production. There were no significant differences in physicochemical properties and index components between the granules obtained by two granulating methods. Dry granulation of Chaiyin granules can reduce the dosage of pharmaceutical excipients, and solve the problems of adhesion and long drying time in wet granulation process.
An LC-MS/MS analytical method was established to determine ipratropium bromide(1) and salbutamol sulfate(2) in compound ipratropium bromide solution(F), thus it was used to determine the distributions of 1 and 2 in tracheobronchial and pulmonary tissues of rats. The results showed that the linear concentration ranges of 1 and 2 in the trachea, bronchus and lung of rats inhaled of F were 2 - 800 and 1 - 400 ng/g, respectively. The dynamic changes of 1 and 2 in rat tracheobronchial and lung tissues showed similar processes, reaching the maximum concentration after administration and followed by rapid elimination. Compound 2 showed higher distribution in trachea and bronchus(P<0.05) than that in lung tissue, and the concentrations of 1 in tracheobronchial and lung tissues showed no significant difference(P>0.05). The developed LC-MS/MS method was simple, sensitive, accurate, and could be used to determine drug distributions in rat tissues. This study provided a new evaluation method for the pharmacokinetics of F in vivo and a reference for clinical rational drug use.
Bromhexine hydrochloride(1) is a commonly used expectorant, showing a polycrystalline phenomenon. Crystal transformation might affect its efficacy. Infrared spectroscopy(IR), powder X-ray diffraction(PXRD), and differential scanning calorimetry(DSC) analyses were adopted to characterize crystal patterns of 1 in its granules and dispersible tablets, and the crystal stability of 1 during the preparation and storage processes was studied. Through IR and PXRD analyses, three different crystal forms of 1 could be identified, while the characterization results of three different crystal forms by DSC were not remarkable. The results indicated that crystal form A of 1 showed good crystal stability and did not undergo crystal transformation during the preparation processes of granules and dispersible tablets or storage under high temperature, light, and high humidity conditions. This paper provided data for improving quality control levels and monitoring the production process.